Molecular Therapy

FIGURE 3

FROM:

A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

Eric J. Small, Michael A. Carducci, James M. Burke, Ron Rodriguez, Lawrence Fong, Lynn van Ummersen, D. C. Yu, Junko Aimi, Dale Ando, Peter Working, David Kirn and George Wilding

BACK TO ARTICLE

Figure 3.

Figure and tables index
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Acute cytokine induction following CG7870 intravenous (IV) infusion. Concentrations of interleukin 6 (IL-6; pg/ml) 6 hours after IV infusion of the virus are represented for each patient per dose cohort (dose levels shown on x-axis); concentrations shown on log scale on y-axis (A). IL-6 concentrations peaked at 6 hours after dosing. Concentrations of interleukin-10 (IL-10; pg/ml) 12–24 hours after IV infusion of the virus are represented for each patient per dose cohort (dose levels shown on x-axis); concentrations shown on linear scale on y-axis (B). IL-10 concentrations peaked between 12 and 24 hours after dosing.

Figure and tables index
BACK TO ARTICLE